KRAS and colorectal carcinoma: Efforts to functionally classify CRC based on mutations to aid prognostication and guide treatment decisions have been largely unsuccessful, with the notable exceptions of microsatellite/MMR status and a handful of actionable mutations in genes such as BRAF and KRAS. This is in contrast to transcriptomic classification, which has shown some promise.